JP5913125B2 - カルボキサミド化合物類およびカルパイン阻害剤ｉｖとしてのこれらの使用 - Google Patents

Info

Publication number

JP5913125B2

JP5913125B2 JP2012545305A JP2012545305A JP5913125B2 JP 5913125 B2 JP5913125 B2 JP 5913125B2 JP 2012545305 A JP2012545305 A JP 2012545305A JP 2012545305 A JP2012545305 A JP 2012545305A JP 5913125 B2 JP5913125 B2 JP 5913125B2

Authority

JP

Japan

Prior art keywords

phenyl

alkyl

dioxo

pyrazol

nicotinamide

Prior art date

2009-12-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• -1 Carboxamide compounds Chemical class 0.000 title claims description 760
• 108010079785 calpain inhibitors Proteins 0.000 title description 24
• 150000001875 compounds Chemical class 0.000 claims description 248
• 125000001072 heteroaryl group Chemical group 0.000 claims description 74
• 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 67
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 58
• 125000003118 aryl group Chemical group 0.000 claims description 55
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 44
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
• 125000001424 substituent group Chemical group 0.000 claims description 41
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
• 229910052799 carbon Inorganic materials 0.000 claims description 34
• 229910052736 halogen Inorganic materials 0.000 claims description 34
• 150000002367 halogens Chemical class 0.000 claims description 33
• 150000003839 salts Chemical class 0.000 claims description 31
• 229910052739 hydrogen Inorganic materials 0.000 claims description 30
• 125000004432 carbon atom Chemical group C* 0.000 claims description 28
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 27
• 229910052757 nitrogen Inorganic materials 0.000 claims description 27
• 208000035475 disorder Diseases 0.000 claims description 25
• 125000000217 alkyl group Chemical group 0.000 claims description 24
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 24
• 235000005152 nicotinamide Nutrition 0.000 claims description 23
• 150000004677 hydrates Chemical class 0.000 claims description 22
• 239000011570 nicotinamide Substances 0.000 claims description 22
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
• 229910052717 sulfur Inorganic materials 0.000 claims description 17
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 15
• 125000005842 heteroatom Chemical group 0.000 claims description 15
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
• 229910052731 fluorine Inorganic materials 0.000 claims description 14
• 230000002829 reductive effect Effects 0.000 claims description 14
• 125000003545 alkoxy group Chemical group 0.000 claims description 12
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
• 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 10
• 208000002193 Pain Diseases 0.000 claims description 10
• 229910052801 chlorine Inorganic materials 0.000 claims description 10
• 230000036407 pain Effects 0.000 claims description 10
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 9
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
• 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 9
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
• 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 8
• 150000003857 carboxamides Chemical class 0.000 claims description 8
• 230000006378 damage Effects 0.000 claims description 8
• 208000014674 injury Diseases 0.000 claims description 7
• 201000004792 malaria Diseases 0.000 claims description 7
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
• 208000024827 Alzheimer disease Diseases 0.000 claims description 6
• 230000008717 functional decline Effects 0.000 claims description 6
• 210000003734 kidney Anatomy 0.000 claims description 6
• DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 5
• 210000004556 brain Anatomy 0.000 claims description 5
• 208000028867 ischemia Diseases 0.000 claims description 5
• 208000002177 Cataract Diseases 0.000 claims description 4
• 102000000589 Interleukin-1 Human genes 0.000 claims description 4
• 108010002352 Interleukin-1 Proteins 0.000 claims description 4
• 206010027476 Metastases Diseases 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 201000005485 Toxoplasmosis Diseases 0.000 claims description 4
• 210000004204 blood vessel Anatomy 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 201000006938 muscular dystrophy Diseases 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 125000004076 pyridyl group Chemical group 0.000 claims description 4
• 208000037803 restenosis Diseases 0.000 claims description 4
• 238000002560 therapeutic procedure Methods 0.000 claims description 4
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 4
• 230000008733 trauma Effects 0.000 claims description 4
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 3
• 125000006771 (C1-C6) haloalkylthio group Chemical group 0.000 claims description 3
• 206010003225 Arteriospasm coronary Diseases 0.000 claims description 3
• 208000003890 Coronary Vasospasm Diseases 0.000 claims description 3
• 208000023105 Huntington disease Diseases 0.000 claims description 3
• 208000018737 Parkinson disease Diseases 0.000 claims description 3
• 208000027418 Wounds and injury Diseases 0.000 claims description 3
• 238000002399 angioplasty Methods 0.000 claims description 3
• 230000003683 cardiac damage Effects 0.000 claims description 3
• 230000004663 cell proliferation Effects 0.000 claims description 3
• 201000011634 coronary artery vasospasm Diseases 0.000 claims description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 3
• 208000001286 intracranial vasospasm Diseases 0.000 claims description 3
• 208000002780 macular degeneration Diseases 0.000 claims description 3
• 208000031225 myocardial ischemia Diseases 0.000 claims description 3
• 230000004770 neurodegeneration Effects 0.000 claims description 3
• 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims description 3
• 210000002027 skeletal muscle Anatomy 0.000 claims description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
• 125000005605 benzo group Chemical group 0.000 claims description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
• 238000002512 chemotherapy Methods 0.000 claims description 2
• 230000001684 chronic effect Effects 0.000 claims description 2
• 208000020832 chronic kidney disease Diseases 0.000 claims description 2
• 230000007812 deficiency Effects 0.000 claims description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 9
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
• 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
• 241000257303 Hymenoptera Species 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• 208000014617 hemorrhoid Diseases 0.000 claims 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
• 108010032088 Calpain Proteins 0.000 description 90
• 102000007590 Calpain Human genes 0.000 description 90
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 86
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 73
• 238000006243 chemical reaction Methods 0.000 description 72
• 239000000203 mixture Substances 0.000 description 38
• 238000005160 1H NMR spectroscopy Methods 0.000 description 33
• 230000005764 inhibitory process Effects 0.000 description 29
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
• 125000001309 chloro group Chemical group Cl* 0.000 description 25
• 210000004185 liver Anatomy 0.000 description 25
• 238000000034 method Methods 0.000 description 25
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
• 241000282414 Homo sapiens Species 0.000 description 23
• 239000003814 drug Substances 0.000 description 23
• 229910052760 oxygen Inorganic materials 0.000 description 23
• 230000000694 effects Effects 0.000 description 22
• 238000011282 treatment Methods 0.000 description 21
• 210000000172 cytosol Anatomy 0.000 description 20
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 19
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
• 239000000651 prodrug Substances 0.000 description 19
• 229940002612 prodrug Drugs 0.000 description 19
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 18
• 229960003966 nicotinamide Drugs 0.000 description 17
• 125000000753 cycloalkyl group Chemical group 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 15
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
• 201000010099 disease Diseases 0.000 description 15
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 14
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
• 239000003112 inhibitor Substances 0.000 description 14
• 108090000712 Cathepsin B Proteins 0.000 description 13
• 102000004225 Cathepsin B Human genes 0.000 description 13
• 108090000625 Cathepsin K Proteins 0.000 description 13
• 102000004171 Cathepsin K Human genes 0.000 description 13
• 108090000624 Cathepsin L Proteins 0.000 description 13
• 102000004172 Cathepsin L Human genes 0.000 description 13
• 108090000613 Cathepsin S Proteins 0.000 description 13
• 239000000460 chlorine Substances 0.000 description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
• 102100035654 Cathepsin S Human genes 0.000 description 12
• 239000002253 acid Substances 0.000 description 12
• 239000001257 hydrogen Substances 0.000 description 12
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
• 125000000623 heterocyclic group Chemical group 0.000 description 11
• 230000002503 metabolic effect Effects 0.000 description 11
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 210000004027 cell Anatomy 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 10
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 9
• 241000725303 Human immunodeficiency virus Species 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 150000001408 amides Chemical class 0.000 description 9
• 150000001721 carbon Chemical group 0.000 description 9
• 239000011737 fluorine Substances 0.000 description 9
• 239000002207 metabolite Substances 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 102000005927 Cysteine Proteases Human genes 0.000 description 8
• 108010005843 Cysteine Proteases Proteins 0.000 description 8
• 230000015556 catabolic process Effects 0.000 description 8
• 230000001086 cytosolic effect Effects 0.000 description 8
• 238000006731 degradation reaction Methods 0.000 description 8
• 125000004438 haloalkoxy group Chemical group 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 7
• 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 7
• 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 7
• 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 7
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 7
• 102000005602 Aldo-Keto Reductases Human genes 0.000 description 7
• 108010084469 Aldo-Keto Reductases Proteins 0.000 description 7
• 241000282693 Cercopithecidae Species 0.000 description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 7
• 239000000020 Nitrocellulose Substances 0.000 description 7
• 239000006180 TBST buffer Substances 0.000 description 7
• 125000003342 alkenyl group Chemical group 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 229920001220 nitrocellulos Polymers 0.000 description 7
• 239000003921 oil Substances 0.000 description 7
• 230000036470 plasma concentration Effects 0.000 description 7
• 150000003254 radicals Chemical class 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
• 150000004799 α-ketoamides Chemical group 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
• 210000003494 hepatocyte Anatomy 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• 239000011541 reaction mixture Substances 0.000 description 6
• 125000006413 ring segment Chemical group 0.000 description 6
• VLSSILIYHTYHQV-BPGUCPLFSA-N (2r)-n-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-1-[(2-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound FC1=CC=CC=C1CN1C(=O)CC[C@@H]1C(=O)NC(C(=O)C(=O)NC1CC1)CC1=CC=CC=C1 VLSSILIYHTYHQV-BPGUCPLFSA-N 0.000 description 5
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 5
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
• 102100035037 Calpastatin Human genes 0.000 description 5
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
• 241000282567 Macaca fascicularis Species 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• FZRKAZHKEDOPNN-UHFFFAOYSA-N Nitric oxide anion Chemical compound O=[N-] FZRKAZHKEDOPNN-UHFFFAOYSA-N 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• 125000002947 alkylene group Chemical group 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 5
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
• 108010044208 calpastatin Proteins 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 230000008030 elimination Effects 0.000 description 5
• 238000003379 elimination reaction Methods 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 150000002431 hydrogen Chemical class 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 229910052740 iodine Inorganic materials 0.000 description 5
• 238000007254 oxidation reaction Methods 0.000 description 5
• 244000045947 parasite Species 0.000 description 5
• 125000004193 piperazinyl group Chemical group 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 108010026424 tau Proteins Proteins 0.000 description 5
• 102000013498 tau Proteins Human genes 0.000 description 5
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
• 206010063897 Renal ischaemia Diseases 0.000 description 4
• 102000005890 Spectrin Human genes 0.000 description 4
• 108010019965 Spectrin Proteins 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 150000001299 aldehydes Chemical class 0.000 description 4
• 125000004414 alkyl thio group Chemical group 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 108010085937 benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide Proteins 0.000 description 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 229910052791 calcium Inorganic materials 0.000 description 4
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000007876 drug discovery Methods 0.000 description 4
• SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 125000001188 haloalkyl group Chemical group 0.000 description 4
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
• 150000002430 hydrocarbons Chemical group 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
• 239000012442 inert solvent Substances 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 230000003647 oxidation Effects 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 150000003217 pyrazoles Chemical class 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 3
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 3
• JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• 102000005600 Cathepsins Human genes 0.000 description 3
• 108010084457 Cathepsins Proteins 0.000 description 3
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 206010029350 Neurotoxicity Diseases 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010037075 Protozoal infections Diseases 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 206010061481 Renal injury Diseases 0.000 description 3
• 206010044221 Toxic encephalopathy Diseases 0.000 description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 description 3
• 150000001241 acetals Chemical class 0.000 description 3
• 229910052783 alkali metal Inorganic materials 0.000 description 3
• 150000001340 alkali metals Chemical class 0.000 description 3
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 150000001733 carboxylic acid esters Chemical class 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000000052 comparative effect Effects 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 239000007822 coupling agent Substances 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 239000012043 crude product Substances 0.000 description 3
• 230000009709 cytosolic degradation Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 229910052805 deuterium Inorganic materials 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 239000003480 eluent Substances 0.000 description 3
• GEVXCKDMGYHHTD-UHFFFAOYSA-N ethyl 3-amino-2-hydroxy-4-phenylbutanoate;hydrochloride Chemical compound [Cl-].CCOC(=O)C(O)C([NH3+])CC1=CC=CC=C1 GEVXCKDMGYHHTD-UHFFFAOYSA-N 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 125000004995 haloalkylthio group Chemical group 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 150000002373 hemiacetals Chemical class 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000002427 irreversible effect Effects 0.000 description 3
• 125000000468 ketone group Chemical group 0.000 description 3
• 210000001853 liver microsome Anatomy 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
• 230000007135 neurotoxicity Effects 0.000 description 3
• 231100000228 neurotoxicity Toxicity 0.000 description 3
• 125000004430 oxygen atom Chemical group O* 0.000 description 3
• 230000004962 physiological condition Effects 0.000 description 3
• 229920000728 polyester Polymers 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 238000000844 transformation Methods 0.000 description 3
• 238000010626 work up procedure Methods 0.000 description 3
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
• IVSZLXZYQVIEFR-UHFFFAOYSA-N 1,3-Dimethylbenzene Natural products CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
• 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 2
• OJMYCATVRPGYJU-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)pyrazol-1-yl]-n-[3-hydroxy-4-oxo-1-phenyl-4-(pyridin-2-ylmethylamino)butan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CC=NC=1CNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC(F)=CC=1)CC1=CC=CC=C1 OJMYCATVRPGYJU-UHFFFAOYSA-N 0.000 description 2
• PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
• SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
• 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• ATNYBKWKPOFGNP-QPIRBTGLSA-N 3-[[(2r)-1-[(2-fluorophenyl)methyl]-5-oxopyrrolidine-2-carbonyl]amino]-2-hydroxy-4-phenylbutanoic acid Chemical compound O=C([C@@H]1N(C(=O)CC1)CC=1C(=CC=CC=1)F)NC(C(O)C(O)=O)CC1=CC=CC=C1 ATNYBKWKPOFGNP-QPIRBTGLSA-N 0.000 description 2
• 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 2
• 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 2
• VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
• 102000003895 Calpain-1 Human genes 0.000 description 2
• 108090000236 Calpain-1 Proteins 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 239000004201 L-cysteine Substances 0.000 description 2
• 235000013878 L-cysteine Nutrition 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 208000029549 Muscle injury Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 2
• 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000002141 anti-parasite Effects 0.000 description 2
• 239000003096 antiparasitic agent Substances 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 2
• NFIKTSWJXJTUBZ-ZEQRLZLVSA-N benzyl n-[2-[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=3OC(=O)C=C(C=3C=C2)C)CCN1C(=O)CNC(=O)OCC1=CC=CC=C1 NFIKTSWJXJTUBZ-ZEQRLZLVSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 229910001424 calcium ion Inorganic materials 0.000 description 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
• 150000003983 crown ethers Chemical class 0.000 description 2
• 125000000000 cycloalkoxy group Chemical group 0.000 description 2
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
• MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 210000004292 cytoskeleton Anatomy 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000036267 drug metabolism Effects 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 230000002045 lasting effect Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
• 230000003228 microsomal effect Effects 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• GASFVSRUEBGMDI-UHFFFAOYSA-N n-aminohydroxylamine Chemical compound NNO GASFVSRUEBGMDI-UHFFFAOYSA-N 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 230000035778 pathophysiological process Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 238000005897 peptide coupling reaction Methods 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 235000008476 powdered milk Nutrition 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 150000003460 sulfonic acids Chemical class 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 150000003512 tertiary amines Chemical class 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 231100000027 toxicology Toxicity 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• YEYWMGLAFZZFLF-SNVBAGLBSA-N (2r)-1-[(2-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCC(=O)N1CC1=CC=CC=C1F YEYWMGLAFZZFLF-SNVBAGLBSA-N 0.000 description 1
• VRTGDYQILDLFPP-WQMHRJNTSA-N (2r)-n-[4-(cyclopropylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-1-[(2-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound C1CC1NC(=O)C(O)C(NC(=O)[C@@H]1N(C(=O)CC1)CC=1C(=CC=CC=1)F)CC1=CC=CC=C1 VRTGDYQILDLFPP-WQMHRJNTSA-N 0.000 description 1
• AHGUSCIGPLCZRU-OPHFCASCSA-N (2s)-2-(benzenesulfonamido)-n-[(1s,2s)-1-hydroxy-3-methyl-1-(3-oxo-2-phenylcyclopropen-1-yl)butan-2-yl]-4-methylpentanamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)[C@@H](O)C=1C(C=1C=1C=CC=CC=1)=O)S(=O)(=O)C1=CC=CC=C1 AHGUSCIGPLCZRU-OPHFCASCSA-N 0.000 description 1
• VLSSILIYHTYHQV-LBAQZLPGSA-N (2s)-n-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-1-[(2-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound FC1=CC=CC=C1CN1C(=O)CC[C@H]1C(=O)NC(C(=O)C(=O)NC1CC1)CC1=CC=CC=C1 VLSSILIYHTYHQV-LBAQZLPGSA-N 0.000 description 1
• HWWSMWYKGHGOHU-UHFFFAOYSA-N (4-oxo-1-phenylbutan-2-yl)carbamic acid Chemical compound OC(=O)NC(CC=O)CC1=CC=CC=C1 HWWSMWYKGHGOHU-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• 125000006079 1,1,2-trimethyl-2-propenyl group Chemical group 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• 125000006059 1,1-dimethyl-2-butenyl group Chemical group 0.000 description 1
• 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 1
• 125000006060 1,1-dimethyl-3-butenyl group Chemical group 0.000 description 1
• 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
• 125000001724 1,2,3-oxadiazol-4-yl group Chemical group [H]C1=C(*)N=NO1 0.000 description 1
• 125000004503 1,2,3-oxadiazol-5-yl group Chemical group O1N=NC=C1* 0.000 description 1
• 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 description 1
• 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 1
• 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
• 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
• 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
• 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 1
• YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
• 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
• 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
• 125000006061 1,2-dimethyl-1-butenyl group Chemical group 0.000 description 1
• 125000006062 1,2-dimethyl-2-butenyl group Chemical group 0.000 description 1
• 125000006063 1,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
• 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
• 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 description 1
• YKUMWOOPDHGKIR-UHFFFAOYSA-N 1,3-benzoxazol-2-ylmethanamine Chemical compound C1=CC=C2OC(CN)=NC2=C1 YKUMWOOPDHGKIR-UHFFFAOYSA-N 0.000 description 1
• 125000006064 1,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
• 125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
• 125000006066 1,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
• OHOXMCCFSFSRMD-UHFFFAOYSA-N 1,3-oxathiole Chemical compound C1OC=CS1 OHOXMCCFSFSRMD-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• 125000006073 1-ethyl-1-butenyl group Chemical group 0.000 description 1
• 125000006080 1-ethyl-1-methyl-2-propenyl group Chemical group 0.000 description 1
• 125000006036 1-ethyl-1-propenyl group Chemical group 0.000 description 1
• 125000006074 1-ethyl-2-butenyl group Chemical group 0.000 description 1
• 125000006081 1-ethyl-2-methyl-1-propenyl group Chemical group 0.000 description 1
• 125000006082 1-ethyl-2-methyl-2-propenyl group Chemical group 0.000 description 1
• 125000006037 1-ethyl-2-propenyl group Chemical group 0.000 description 1
• 125000006075 1-ethyl-3-butenyl group Chemical group 0.000 description 1
• 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
• 125000006044 1-methyl-1-pentenyl group Chemical group 0.000 description 1
• 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
• 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
• 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 1
• 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
• 125000006030 1-methyl-3-butenyl group Chemical group 0.000 description 1
• 125000006052 1-methyl-3-pentenyl group Chemical group 0.000 description 1
• 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 1
• 125000006018 1-methyl-ethenyl group Chemical group 0.000 description 1
• 125000006023 1-pentenyl group Chemical group 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
• 150000003990 18-crown-6 derivatives Chemical group 0.000 description 1
• NEUWPDLMDVINSN-UHFFFAOYSA-N 1h-pyrazol-5-ylboronic acid Chemical compound OB(O)C=1C=CNN=1 NEUWPDLMDVINSN-UHFFFAOYSA-N 0.000 description 1
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• 125000004781 2,2-dichloro-2-fluoroethyl group Chemical group [H]C([H])(*)C(F)(Cl)Cl 0.000 description 1
• 125000006067 2,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
• XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
• 125000006068 2,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
• 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
• 125000006070 2,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
• LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 description 1
• MEXMYDPTOZRZLZ-UHFFFAOYSA-N 2-(3-cyclopropylpyrazol-1-yl)-n-[3-hydroxy-4-(methoxyamino)-4-oxo-1-phenylbutan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=C(N2N=C(C=C2)C2CC2)C=1C(=O)NC(C(O)C(=O)NOC)CC1=CC=CC=C1 MEXMYDPTOZRZLZ-UHFFFAOYSA-N 0.000 description 1
• YRYWJUPAZPFJMT-UHFFFAOYSA-N 2-(4-fluoro-3-phenylpyrazol-1-yl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1N1N=C(C=2C=CC=CC=2)C(F)=C1 YRYWJUPAZPFJMT-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
• ZWAFSFBMKWXCBN-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)pyrazol-1-yl]-n-[3-hydroxy-4-oxo-1-phenyl-4-(2-phenylethylamino)butan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CC=CC=1CCNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC(F)=CC=1)CC1=CC=CC=C1 ZWAFSFBMKWXCBN-UHFFFAOYSA-N 0.000 description 1
• UQIOOUHEOLQBQU-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)pyrazol-1-yl]-n-[3-hydroxy-4-oxo-1-phenyl-4-(2-pyridin-2-ylethylamino)butan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CC=NC=1CCNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC(F)=CC=1)CC1=CC=CC=C1 UQIOOUHEOLQBQU-UHFFFAOYSA-N 0.000 description 1
• ZHUKPGFMVLVVRE-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)pyrazol-1-yl]-n-[3-hydroxy-4-oxo-1-phenyl-4-(3-pyridin-2-ylpropylamino)butan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CC=NC=1CCCNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC(F)=CC=1)CC1=CC=CC=C1 ZHUKPGFMVLVVRE-UHFFFAOYSA-N 0.000 description 1
• NLHRMZKHFKJPNO-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)pyrazol-1-yl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1N1N=C(C=2C=CC(F)=CC=2)C=C1 NLHRMZKHFKJPNO-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• 125000005999 2-bromoethyl group Chemical group 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 1
• 125000004779 2-chloro-2-fluoroethyl group Chemical group [H]C([H])(*)C([H])(F)Cl 0.000 description 1
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
• KKZUMAMOMRDVKA-UHFFFAOYSA-N 2-chloropropane Chemical group [CH2]C(C)Cl KKZUMAMOMRDVKA-UHFFFAOYSA-N 0.000 description 1
• 125000006077 2-ethyl-2-butenyl group Chemical group 0.000 description 1
• 125000006078 2-ethyl-3-butenyl group Chemical group 0.000 description 1
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
• 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
• 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 1
• 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
• 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
• 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
• 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
• 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
• 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 description 1
• 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004326 2H-pyran-2-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])(*)O1 0.000 description 1
• VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical class C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
• 125000006071 3,3-dimethyl-1-butenyl group Chemical group 0.000 description 1
• 125000006072 3,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
• AOWQRSBWEZCZSQ-UHFFFAOYSA-N 3-amino-n-cyclopropyl-2-hydroxy-4-phenylbutanamide Chemical compound C1CC1NC(=O)C(O)C(N)CC1=CC=CC=C1 AOWQRSBWEZCZSQ-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
• 125000006046 3-methyl-1-pentenyl group Chemical group 0.000 description 1
• 125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 1
• 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
• 125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 1
• 125000006057 3-methyl-4-pentenyl group Chemical group 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000006042 4-hexenyl group Chemical group 0.000 description 1
• OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 description 1
• 125000006047 4-methyl-1-pentenyl group Chemical group 0.000 description 1
• 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
• 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000004315 4H-pyran-2-yl group Chemical group [H]C1=C([H])C([H])([H])C([H])=C(*)O1 0.000 description 1
• 125000006043 5-hexenyl group Chemical group 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
• 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
• 102000005862 Angiotensin II Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• VWBBJOQMOXDXOT-UHFFFAOYSA-N C1=CC=C(C=C1)CC(C(=O)C(=O)NCC2=CC=CC=N2)N3C=CC=CC3N4C=CC(=N4)C5=CC=CC=C5 Chemical compound C1=CC=C(C=C1)CC(C(=O)C(=O)NCC2=CC=CC=N2)N3C=CC=CC3N4C=CC(=N4)C5=CC=CC=C5 VWBBJOQMOXDXOT-UHFFFAOYSA-N 0.000 description 1
• YHNMEWSQGWBZMR-UHFFFAOYSA-N C1CC(=O)N(C1C(=O)NF)CC2=CC=CC=C2 Chemical compound C1CC(=O)N(C1C(=O)NF)CC2=CC=CC=C2 YHNMEWSQGWBZMR-UHFFFAOYSA-N 0.000 description 1
• VDQSPUBAFVHLMB-UHFFFAOYSA-N C1CC(N(C1=O)CC2=CC=CC=C2)(C(=O)O)F Chemical compound C1CC(N(C1=O)CC2=CC=CC=C2)(C(=O)O)F VDQSPUBAFVHLMB-UHFFFAOYSA-N 0.000 description 1
• 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
• 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
• 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
• 229940121926 Calpain inhibitor Drugs 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 101150053721 Cdk5 gene Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
• 235000000385 Costus speciosus Nutrition 0.000 description 1
• 244000258136 Costus speciosus Species 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
• 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 239000004129 EU approved improving agent Substances 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000013875 Heart injury Diseases 0.000 description 1
• 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
• 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
• 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
• 208000004454 Hyperalgesia Diseases 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004125 Interleukin-1alpha Human genes 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 102000008934 Muscle Proteins Human genes 0.000 description 1
• 108010074084 Muscle Proteins Proteins 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• HPAQSPOQUHTHJC-UHFFFAOYSA-N N-[4-(2-fluorophenyl)pyrazol-1-yl]pyridine-3-carboxamide Chemical compound N1=CC(=CC=C1)C(=O)NN1N=CC(=C1)C1=C(C=CC=C1)F HPAQSPOQUHTHJC-UHFFFAOYSA-N 0.000 description 1
• RIYLNECMTVNMSO-GOTSBHOMSA-N N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 RIYLNECMTVNMSO-GOTSBHOMSA-N 0.000 description 1
• 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
• 102000003797 Neuropeptides Human genes 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• PJIHCWJOTSJIPQ-AGFFZDDWSA-N S-(cis-1,2-dichlorovinyl)-L-cysteine Chemical compound OC(=O)[C@@H](N)CS\C(Cl)=C\Cl PJIHCWJOTSJIPQ-AGFFZDDWSA-N 0.000 description 1
• 239000012722 SDS sample buffer Substances 0.000 description 1
• 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 1
• 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 238000006859 Swern oxidation reaction Methods 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000034799 Tauopathies Diseases 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
• 150000008046 alkali metal hydrides Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004450 alkenylene group Chemical group 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 230000000078 anti-malarial effect Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 125000005018 aryl alkenyl group Chemical group 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001559 benzoic acids Chemical class 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 150000001565 benzotriazoles Chemical class 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• PJYGPNGTUCHYIC-UHFFFAOYSA-N bis(1h-pyrazol-5-yl)methanone Chemical compound C1=CNN=C1C(=O)C=1C=CNN=1 PJYGPNGTUCHYIC-UHFFFAOYSA-N 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 208000025698 brain inflammatory disease Diseases 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 235000014121 butter Nutrition 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 108010007877 calpain inhibitor III Proteins 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 150000001728 carbonyl compounds Chemical class 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 239000001913 cellulose Chemical class 0.000 description 1
• 229920002678 cellulose Chemical class 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000003793 centrosome Anatomy 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
• 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
• 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000003271 compound fluorescence assay Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
• 150000001975 deuterium Chemical group 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
• 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000011496 digital image analysis Methods 0.000 description 1
• 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 150000002118 epoxides Chemical class 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
• NDNQGBWQXWLZDW-UHFFFAOYSA-N ethyl 2-(4-fluoro-3-phenylpyrazol-1-yl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1N1N=C(C=2C=CC=CC=2)C(F)=C1 NDNQGBWQXWLZDW-UHFFFAOYSA-N 0.000 description 1
• PMIMPBYTPPRBGD-UHFFFAOYSA-N ethyl 2-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1Cl PMIMPBYTPPRBGD-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 231100000318 excitotoxic Toxicity 0.000 description 1
• 230000003492 excitotoxic effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 230000004424 eye movement Effects 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000010579 first pass effect Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 208000010710 hepatitis C virus infection Diseases 0.000 description 1
• 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
• 150000002391 heterocyclic compounds Chemical class 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 150000002429 hydrazines Chemical class 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 230000006951 hyperphosphorylation Effects 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000013067 intermediate product Substances 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 244000000056 intracellular parasite Species 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 150000002497 iodine compounds Chemical class 0.000 description 1
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
• 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
• 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
• 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 1
• 230000005445 isotope effect Effects 0.000 description 1
• 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
• 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 208000037806 kidney injury Diseases 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 210000002311 liver mitochondria Anatomy 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 108010011767 m-calpain Proteins 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 239000002075 main ingredient Substances 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000007334 memory performance Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 230000006667 mitochondrial pathway Effects 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 230000001095 motoneuron effect Effects 0.000 description 1
• 108010068164 mu-calpain Proteins 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• QYLRJPYLDJPSBC-UHFFFAOYSA-N n-(4-phenylbutan-2-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCC1=CC=CC=C1 QYLRJPYLDJPSBC-UHFFFAOYSA-N 0.000 description 1
• JZOJZBKAQUYQTP-UHFFFAOYSA-N n-[3-hydroxy-4-(methylamino)-4-oxo-1-phenylbutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=C(N2N=C(C=C2)C=2C=CC=CC=2)C=1C(=O)NC(C(O)C(=O)NC)CC1=CC=CC=C1 JZOJZBKAQUYQTP-UHFFFAOYSA-N 0.000 description 1
• CIAVEEZRQBFCHM-UHFFFAOYSA-N n-[3-hydroxy-4-oxo-1-phenyl-4-(2-phenylethylamino)butan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C=1C=CC=CC=1CCNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 CIAVEEZRQBFCHM-UHFFFAOYSA-N 0.000 description 1
• OPEKBCBVSMEASG-UHFFFAOYSA-N n-[3-hydroxy-4-oxo-1-phenyl-4-(propylamino)butan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=C(N2N=C(C=C2)C=2C=CC=CC=2)C=1C(=O)NC(C(O)C(=O)NCCC)CC1=CC=CC=C1 OPEKBCBVSMEASG-UHFFFAOYSA-N 0.000 description 1
• OSQHTXSNTBJJSX-UHFFFAOYSA-N n-[3-hydroxy-4-oxo-1-phenyl-4-(pyridin-2-ylmethylamino)butan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C=1C=CC=NC=1CNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 OSQHTXSNTBJJSX-UHFFFAOYSA-N 0.000 description 1
• KMBLSBZIXJKAAV-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-ylmethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound N=1C2=CC=CC=C2OC=1CNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 KMBLSBZIXJKAAV-UHFFFAOYSA-N 0.000 description 1
• INJYBFTVEOFCHH-UHFFFAOYSA-N n-[4-(benzylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C=1C=CC=CC=1CNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 INJYBFTVEOFCHH-UHFFFAOYSA-N 0.000 description 1
• WIKJLKQOXLDTTO-UHFFFAOYSA-N n-[4-(cyclobutylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C1CCC1NC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 WIKJLKQOXLDTTO-UHFFFAOYSA-N 0.000 description 1
• HVYXPXBRMXOYPV-UHFFFAOYSA-N n-[4-(cyclopropylamino)-1-(4-fluorophenyl)-3-hydroxy-4-oxobutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C1CC1NC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=C(F)C=C1 HVYXPXBRMXOYPV-UHFFFAOYSA-N 0.000 description 1
• VLSSILIYHTYHQV-UHFFFAOYSA-N n-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-1-[(2-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide Chemical compound FC1=CC=CC=C1CN1C(=O)CCC1C(=O)NC(C(=O)C(=O)NC1CC1)CC1=CC=CC=C1 VLSSILIYHTYHQV-UHFFFAOYSA-N 0.000 description 1
• IRNOXDRPZNWCQG-UHFFFAOYSA-N n-[4-(cyclopropylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C1CC1NC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 IRNOXDRPZNWCQG-UHFFFAOYSA-N 0.000 description 1
• SJSAVPFZOBKCNO-UHFFFAOYSA-N n-[4-(cyclopropylmethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(3-phenylpyrazol-1-yl)pyridine-3-carboxamide Chemical compound C1CC1CNC(=O)C(O)C(NC(=O)C=1C(=NC=CC=1)N1N=C(C=C1)C=1C=CC=CC=1)CC1=CC=CC=C1 SJSAVPFZOBKCNO-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000957 no side effect Toxicity 0.000 description 1
• 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
• 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
• 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000001328 optic nerve Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
• 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000037324 pain perception Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000012660 pharmacological inhibitor Substances 0.000 description 1
• 229950009215 phenylbutanoic acid Drugs 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 108010028016 procathepsin K Proteins 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• QLNJFJADRCOGBJ-LBPDFUHNSA-N propanamide Chemical class CC[13C](N)=O QLNJFJADRCOGBJ-LBPDFUHNSA-N 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000006920 protein precipitation Effects 0.000 description 1
• 230000007026 protein scission Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
• 150000003218 pyrazolidines Chemical class 0.000 description 1
• 150000003219 pyrazolines Chemical class 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
• 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical class C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000004151 quinonyl group Chemical group 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 210000003752 saphenous vein Anatomy 0.000 description 1
• 238000007127 saponification reaction Methods 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000020341 sensory perception of pain Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 108010027126 short chain trans-2-enoyl-CoA reductase Proteins 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• KSMOVGKUTMEDSD-UHFFFAOYSA-N tert-butyl n-[4-(cyclopropylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]carbamate Chemical compound C1CC1NC(=O)C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 KSMOVGKUTMEDSD-UHFFFAOYSA-N 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004297 tetrahydropyrrol-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 1
• 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
• 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 238000002627 tracheal intubation Methods 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 150000003628 tricarboxylic acids Chemical class 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• 210000003934 vacuole Anatomy 0.000 description 1
• 238000007631 vascular surgery Methods 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1